N-Gene Research Laboratories, Inc. Reports Positive Phase II Results With BGP-15 Insulin Sensitizer

NEW YORK, June 12 /PRNewswire/ -- N-Gene Research Laboratories, Inc., a privately held biopharmaceutical company developing products to treat insulin resistance, today presented positive Phase II data for BGP-15, a novel insulin sensitizer. The data were presented in a poster presentation at the American Diabetes Association 66th Scientific Sessions conference in Washington, DC, titled "BGP-15, a Novel Insulin Sensitizer." Presenters included Jesse Roth, M.D., Professor of Medicine, Albert Einstein College of Medicine, former Scientific Director of National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of National Institutes of Health (NIH); and Kalman Tory, M.D., Head of Cellular and Molecular Pharmacology, N-Gene Research Laboratories.